We are also collaborating with South Korean pharmaceutical company, SK bioscience, on a vaccine. Following phase 3 results in December 2021, approval for use was granted by Health Canada in February 2022. Our collaboration with Canadian biopharmaceutical company, Medicago, created a unique vaccine using their plant-based technology. In February 2022, following phase 3 study results, we announced we would seek marketing authorisations. This is valuable during a pandemic when a vaccine must be produced in large quantities. This may allow for more doses to be produced because a smaller amount of vaccine is needed to generate immunity. We partnered with several companies working on vaccines by providing them with access to our adjuvant technology.Īdding an adjuvant to a vaccine can improve the immune system’s response to the vaccine.
![die antwoord tour 2021 usa die antwoord tour 2021 usa](https://i.ytimg.com/vi/FhFFMTJ6tG4/maxresdefault.jpg)
A phase 1/2 study in patients with mild to moderate COVID-19 is underway. The second antibody from our collaboration with Vir is also being investigated as a potential treatment. In December 2021, the European Commission approved the same monoclonal antibody for use in the European Union. In May 2021, we received Emergency Use Authorisation from the US Food and Drug Administration for the first of these monoclonal antibodies. Monoclonal antibodies work in a similar way to the human immune system and could be an important intervention for people who do not have a strong natural immune response to a virus. This enables multiple antibodies that will target the virus to be produced. Monoclonal antibodies are created in a lab by cloning an antibody that has been exposed to a specific virus. We are collaborating with US immunology company, Vir Biotechnology, to investigate two monoclonal antibodies that target the COVID-19 virus.